Madrigal Pharmaceuticals Inc. (MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis, is on the verge of a crucial event this week.
Non-alcoholic steatohepatitis, or NASH, a more advanced form of non-alcoholic fatty liver disease, is a leading cause of liver related mortality. People with NASH have an increased risk of heart attack, stroke and death. There are no FDA-approved treatments for the disease, yet.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com